Brexpiprazole
Phase 3Completed 0 watching 0 views this week📈 Rising
74
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Irritability Associated With Autism Spectrum Disorder
Conditions
Irritability Associated With Autism Spectrum Disorder
Trial Timeline
Jan 23, 2020 → Mar 16, 2023
NCT ID
NCT04258839About Brexpiprazole
Brexpiprazole is a phase 3 stage product being developed by Lundbeck for Irritability Associated With Autism Spectrum Disorder. The current trial status is completed. This product is registered under clinical trial identifier NCT04258839. Target conditions include Irritability Associated With Autism Spectrum Disorder.
Hype Score Breakdown
Clinical
27
Activity
18
Company
7
Novelty
9
Community
10
Clinical Trials (11)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05504486 | Approved | Withdrawn |
| NCT04830215 | Approved | Completed |
| NCT04258839 | Phase 3 | Completed |
| NCT03548584 | Phase 3 | Completed |
| NCT03287869 | Phase 3 | Completed |
| NCT03292848 | Phase 1 | Completed |
| NCT03238326 | Phase 3 | Completed |
| NCT01944969 | Phase 3 | Terminated |
| NCT01942785 | Phase 3 | Completed |
| NCT01942733 | Phase 3 | Completed |
| NCT01810783 | Phase 3 | Completed |
Competing Products
7 competing products in Irritability Associated With Autism Spectrum Disorder
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| KarXT + KarX-EC + KarXT + KarX-EC Matching Placebo | Bristol Myers Squibb | Phase 3 | 76 |
| KarXT + KarX-EC + KarXT + KarX-EC Matching Placebo | Bristol Myers Squibb | Phase 3 | 76 |
| Aripiprazole + Placebo | Bristol Myers Squibb | Approved | 84 |
| Brexpiprazole + Placebo | Lundbeck | Phase 3 | 74 |
| JZP541 | Jazz Pharmaceuticals | Phase 2 | 49 |
| Pimavanserin | Acadia Pharmaceuticals | Phase 2/3 | 60 |
| Pimavanserin + Placebo | Acadia Pharmaceuticals | Phase 2/3 | 60 |